Is Bio-Techne Corporation (TECH) a High-Quality Growth-Oriented Compounder Within The Healthcare Sector?

3 days ago 3

Soumya Eswaran

Thu, November 13, 2025 astatine 8:01 AM CST 3 min read

ClearBridge Investments, an concern absorption company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In an situation of shifting monetary policy, stabilizing earnings, and improved sentiment, midcaps experienced maturation successful the 3rd quarter. The Federal Reserve’s determination to chopped rates helped tiny and mid-cap stocks successful the quarter. Value stocks outperformed their maturation counterparts with the Russell Midcap Value Index returning 6.2% compared to the Russell Midcap Growth’s 2.8% return. In this environment, the strategy outperformed its Russell Midcap Index during the 3rd quarter. Stock enactment successful the user staples and healthcare sectors drove outperformance of the strategy. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, ClearBridge Mid Cap Strategy highlighted stocks specified arsenic Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a marketplace capitalization of $9.57billion, develops, manufactures, and sells beingness subject reagents, instruments, and services for the probe and objective diagnostic markets. The one-month instrumentality of Bio-Techne Corporation (NASDAQ:TECH) was -0.32%, and its shares mislaid 15.36% of their worth implicit the past 52 weeks. On November 12, 2025, Bio-Techne Corporation (NASDAQ:TECH) banal closed astatine $61.40 per share.

ClearBridge Mid Cap Strategy stated the pursuing regarding Bio-Techne Corporation (NASDAQ:TECH) successful its 3rd 4th 2025 capitalist letter:

"Complementing the occurrence of our wellness attraction holdings, we initiated a caller presumption successful Bio-Techne Corporation (NASDAQ:TECH), a starring supplier of beingness sciences tools and diagnostics utilized successful biologic research, objective investigating and biopharmaceutical manufacturing. We capitalized connected caller weakness successful the sanction tied to uncertainty surrounding tariffs and National Institute of Health backing to initiate a presumption successful the company, whose high-margin consumables and instrumentation portfolio supply durable recurring gross streams. This recurring revenue, on with biopharma and world vulnerability and an charismatic introduction terms underscore Bio-Techne’s entreaty arsenic a high-quality growth-oriented compounder wrong wellness care."

8 Most Promising Medical Stocks According to Hedge Funds

Bio-Techne Corporation (NASDAQ:TECH) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 37 hedge money portfolios held Bio-Techne Corporation (NASDAQ:TECH) astatine the extremity of the 2nd quarter, compared to 34 successful the erstwhile quarter. In the fiscal archetypal 4th of 2026, Bio-Techne Corporation (NASDAQ:TECH) generated $286.6 million, successful revenues, down 1% year-over-year some connected integrated ground and reported basis. While we admit the imaginable of Bio-Techne Corporation (NASDAQ:TECH) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.